# Non-inferiority Study to Compare the Efficacy and Safety of Mylan's Insulin Glargine With Lantus® in Type 2 Diabetes Mellitus Patients (INSTRIDE 2)

Study · id `cardio:ct-nct02227875` · Cardiovascular Atlas · release `a25293eeae6350fb` (public)

> General information from published sources, not medical advice, and not reviewed by clinicians. Check the cited source before relying on anything here. Sponsors do not influence what this atlas says.

The atlas's own text and curation may be reused under Creative Commons Attribution-NonCommercial 4.0 International (CC BY-NC 4.0, https://creativecommons.org/licenses/by-nc/4.0/): credit the atlas, and do not use it commercially without a licence from the owner. See the atlas About page. Text quoted from a source stays under that source's own terms, given as the source's reuse\_basis. The atlas's reuse terms do not cover it. The downloads list each quotation with its source in third\_party\_quotations.

**Registry record.** Assembled by a program from [ClinicalTrials.gov record NCT02227875](<https://clinicaltrials.gov/study/NCT02227875>), retrieved 26 October 2026. No person wrote or checked this page.

Also called: NCT02227875

Browse, organ or system: Metabolism  
Browse, condition area: Diabetes and metabolic disease  

## In plain language

A phase 3 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 560 participants.

## Technical summary

Registry record NCT02227875. Randomized; no masking; primary purpose treatment. Start 2014-08 (registry gives no type); primary completion 2015-12 (actual). Results posted on 2020-08-13.

## Key facts

- Design: Interventional study; randomized; no masking; primary purpose treatment
- Phase: Phase 3
- Enrolled: 560 participants (enrolled count; ClinicalTrials.gov record NCT02227875, source copy `cardio:ctgov-nct02227875-2022-03-03`, retrieved 2026-10-26)
- Start date: 2014-08 (registry gives no type) (ClinicalTrials.gov record NCT02227875, source copy `cardio:ctgov-nct02227875-2022-03-03`, retrieved 2026-10-26)
- Primary completion: 2015-12 (actual) (ClinicalTrials.gov record NCT02227875, source copy `cardio:ctgov-nct02227875-2022-03-03`, retrieved 2026-10-26)
- Completion: 2015-12 (actual) (ClinicalTrials.gov record NCT02227875, source copy `cardio:ctgov-nct02227875-2022-03-03`, retrieved 2026-10-26)
- Results first posted: 2020-08-13 (ClinicalTrials.gov record NCT02227875, source copy `cardio:ctgov-nct02227875-2022-03-03`, retrieved 2026-10-26)
- Countries: United States; Jordan; Slovakia; South Africa; South Korea; Taiwan (ClinicalTrials.gov record NCT02227875, source copy `cardio:ctgov-nct02227875-2022-03-03`, retrieved 2026-10-26)
- Care setting: Not reported
- Registry status: "COMPLETED" (U.S. National Library of Medicine (ClinicalTrials.gov), source copy `cardio:ctgov-nct02227875-2022-03-03`, retrieved 2026-10-26)

## The registry's words

- Brief title: Non-inferiority Study to Compare the Efficacy and Safety of Mylan's Insulin Glargine With Lantus® in Type 2 Diabetes Mellitus Patients (INSTRIDE 2)
- Acronym: INSTRIDE 2
- Condition: Type 2 Diabetes
- Intervention (Drug): Mylan's insulin glargine
- Intervention (Drug): Lantus®
- Lead sponsor: Mylan Inc.
- Lead sponsor class: INDUSTRY
- Collaborator: Mylan GmbH
- Collaborator class: INDUSTRY

## Connected pages

- Registry condition terms include this condition: Type 2 diabetes (`cardio:type-2-diabetes`)

## Provenance

Content hash: ae12d6659a81b84031caca664d96c9c4934d58449bcf39b116a1377a33a7afa6
Last substantive edit: 2026-10-26
Evidence last checked: Not recorded
